Poseida Therapeutics
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies to treat life-threatening cancers and genetic diseases. They leverage proprietary genetic editing platforms, including non-viral piggyBac DNA Delivery System and Cas-CLOVER site-specific gene editing, to create next-generation therapeutics. The company has formed strategic collaborations with Roche and Takeda, and is committed to advancing treatments with the capacity to cure certain cancers and rare diseases.
Industries
Nr. of Employees
large (251-1000)
Poseida Therapeutics
Patents
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
US-11744861-B2
View DetailsCompositions and methods for directing proteins to specific loci in the genome
US-11473082-B2
View Details
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
US-11744861-B2
View DetailsCompositions and methods for directing proteins to specific loci in the genome
US-11473082-B2
View DetailsProducts
Allogeneic anti-BCMA CAR-T candidate (clinical Phase 1b)
An off-the-shelf allogeneic CAR-T program targeting BCMA for treatment of multiple myeloma; clinical Phase 1b activity reported.
Allogeneic dual CD19/CD20 CAR-T candidate (Phase 1, preclinical data available)
A dual-target allogeneic CAR-T program against CD19 and CD20 for B-cell malignancies with preclinical data and early clinical investigation.
Autologous PSMA-targeting CAR-T candidate (Phase 1)
An autologous CAR-T program targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer; Phase 1 patient dosing completed.
Allogeneic anti-BCMA CAR-T candidate (clinical Phase 1b)
An off-the-shelf allogeneic CAR-T program targeting BCMA for treatment of multiple myeloma; clinical Phase 1b activity reported.
Allogeneic dual CD19/CD20 CAR-T candidate (Phase 1, preclinical data available)
A dual-target allogeneic CAR-T program against CD19 and CD20 for B-cell malignancies with preclinical data and early clinical investigation.
Autologous PSMA-targeting CAR-T candidate (Phase 1)
An autologous CAR-T program targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer; Phase 1 patient dosing completed.
Services
Collaborative research agreements and license arrangements to combine genetic engineering platforms and develop partnered cell therapy programs.
Design and conduct of Phase 1 / Phase 1b clinical trials for cell therapy candidates, including patient enrollment and dosing operations.
GMP-capable manufacturing and supply for cell therapy clinical programs with processes optimized for non-viral engineered products.
Collaborative research agreements and license arrangements to combine genetic engineering platforms and develop partnered cell therapy programs.
Design and conduct of Phase 1 / Phase 1b clinical trials for cell therapy candidates, including patient enrollment and dosing operations.
GMP-capable manufacturing and supply for cell therapy clinical programs with processes optimized for non-viral engineered products.
Expertise Areas
- Allogeneic CAR-T development
- Autologous CAR-T development and early-phase clinical trials
- Non-viral gene engineering
- Cell therapy process development and scale-up
Key Technologies
- Non-viral transposon-mediated genome integration
- High-fidelity site-specific nuclease editing
- Nanoparticle-mediated gene delivery
- AAV-based gene delivery